Long-Term Outcomes of Femoral Derotation Osteotomy for Individuals With Cerebral Palsy
NCT ID: NCT03444116
Last Updated: 2021-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2017-09-12
2019-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controlling Femoral Extension and Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking
NCT03528889
Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking
NCT03518541
Hip Reconstruction in Cerebral Palsy With Pelvic Osteotomy
NCT02372617
Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy
NCT02699554
Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia
NCT01381198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Short-term (\~12 months postoperative) improvements of transverse plane hip rotation during gait range from only 33% to 94%. Despite FDO's widespread use, long-term outcomes of the procedure have only begun to be studied, with our 2016 study the only one that included a control group. Without a control group, the natural history of bony remodeling or gait adaptations is unknown. However, our prior study is limited by two main factors, 1) all data were extracted from our database retrospectively, so the potential for a large bias exists since outcomes reflect only patients with clinically-initiated gait visits, and 2) outcomes of hip abductor function were only measured by hip rotation (or hip abductor moment during gait, which is only available for individuals who can walk without assistive devices), so the true ability of the hip abductors to generate moment has not been tested. Furthermore, the vast majority of individuals were \<18 years old at their "long-term" visit (\~5 years after their preoperative gait visit), which precedes the reported gait or functional decline more commonly occurring in one's 20s and beyond.
Counseling families on the long-term outcomes after an FDO is currently not possible and is necessary for families and health-care providers to make informed decisions. It remains unclear whether individuals who receive an FDO experience long-term beneficial effects on function, activity, and comfort as compared to those who receive other or no treatment for their excessive anteversion and/or IHR.
Briefly, anteversion as measured by the trochanteric prominence angle test (TPAT) is the most common method used by clinicians to determine if an FDO is warranted, in addition to anteversion being an important predictor of predicted short-term outcomes after an FDO23. However, data from our lab suggests that there is 10-15° of measurement error associated with this method. As such, our secondary purpose was to compare anteversion as measured by the TPAT to that of a radiographical gold standard, EOS. EOS delivers 4-30 times less radiation to the gonads and lower extremities compared to computed tomography (CT)24, making it very suitable for research purposes. Additionally, accuracy of quantifying femoral anteversion is not compromised versus the current gold standard, CT, with a mean difference of \~3° reported.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases (+FDO)
Patients who underwent an FDO
Motion Analysis
Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
sterEOS Imaging of Lower Extremities
Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
Surveys
9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
Controls (-FDO)
Same as cases but did not undergo an FDO
Motion Analysis
Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
sterEOS Imaging of Lower Extremities
Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
Surveys
9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Motion Analysis
Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
sterEOS Imaging of Lower Extremities
Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
Surveys
9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minimum age of 25 years presently
* Had a preoperative gait analysis
* Underwent only 1 external, proximal FDO per side
* Minimum 5 years since an FDO
* FDO implants have been removed
* No prior pelvic osteotomy
* Able to speak and read English
* Not pregnant
Control group (-FDO):
* Same as cases, except no FDO
* Matched to cases at baseline (using a matching algorithm)
Exclusion Criteria
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gillette Children's Specialty Healthcare
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tom F Novacheck
Pediatric Orthopedic Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tom F Novacheck, MD
Role: PRINCIPAL_INVESTIGATOR
Gillette Children's Specialty Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Study 00000239
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.